Table 1 Characteristics of 16 Trials Meeting Criteria for Inclusion in the Meta-analysis
Study | Diagnoses | Country | Age, | High-intensity statin | Standard statin | Follow-up Time |
|---|---|---|---|---|---|---|
Armitage et al., 2010 [18] | History of MI | UK Multi-center trial | 64.2 ± 8.9 | Simvastatin 80 mg | Simvastatin 20 mg | 2, 12, 24, and 36 months |
Cannon et al., 2004 [1] | ACS | International Multi-center trial | 58 | Atorvastatin 80 mg | Pravastatin 40 mg | 1, 3, 4, and 24 months |
Colivicchi et al., 2010 [26] | Non-STEMI | Italy Multi-center trial | 75.2 ± 9.9/73.9 ± 9.4 | Atorvastatin 80 mg | Atorvastatin 20 mg | 12 months |
Colivicchi et al., 2002 [27] | UA or Non Q Wave MI | Italy Multi-center trial | 69/68 | Atorvastatin 80 mg | Usual care | 1, 4, and 12 months |
De Lemos et al., 2004 [28] | ACS | International Multi-center trial | 61/61 | Simvastatin 40 mg 1 month follow by 80 mg | Placebo 4 months follow by simvastatin 20 mg | 24 months |
Im et al., 2018 [25] | ACS | Korea Multi-center trial | 64 ± 12/64 ± 12 | Atorvastatin 40 mg | Pravastatin 20 mg | 12 months |
Guo et al., 2017 [24] | ACS after stent implantation | Chinese Single-center trial | 57.8 ± 6.4/62.3 ± 3.7 | Rosuvastatin 20 mg | Rosuvastatin 10 mg | 3 months |
Liu et al., 2019 [6] | Acute STEMI undergoing emergency PCI | Chinese Single-center trial | 58.4/60.5 | Atorvastatin 40 mg | Atorvastatin 20 mg | 12 months |
Liu et al., 2016 [21] | ACS requiring PCI | Chinese Single-center trial | 61.8 ± 10.1/62.5 ± 11.2 | Atorvastatin 80 mg | Atorvastatin 20 mg | 1 and 12 months |
Liu et al., 2016 [20] | ACS with DM underwent primary or Early PCI | Chinese Single-center trial | 61.6 ± 8.7/62.1 ± 10.2 | Atorvastatin 40 mg | Atorvastatin 20 mg | 1 and 12 months |
Priti et al., 2017 [19] | Acute STEMI | India Single-center trial | 56.64/57.35 | Atorvastatin 80 mg | Atorvastatin 10 mg | 1 month |
Shehata et al., 2015 [17] | NSTE-ACS | Egypt Single-center trial | 58 ± 9/57 ± 8 | Atorvastatin 80 mg | Atorvastatin 20 mg | 6 months |
Shehata et al., 2017 [16] | NSTE-ACS | Egypt Single-center trial | 56 ± 9/55 ± 11 | Atorvastatin 80 mg | Atorvastatin 20 mg | 3 months |
Pedersen et al., 2010 [23] | Had a first acute MI < 2 months before randomization | Dutch Multi-center trial | 60.6 ± 9.7/59.8 ± 9.6 | Atorvastatin 80 mg | Simvastatin 20 to 40 mg | over 5 years |
Zhao et al., 2014 [7] | ACS | Chinese Multi-center trial | 60.8/60.4 | Atorvastatin 20 or 40 mg | Atorvastatin 10 mg | 24 months |
Zheng et al., 2015 [22] | NSTEMI | Chinese Multi-center trial | 59.47 ± 8.6/59.70 ± 8.4 | Atorvastatin 40 mg | Atorvastatin ≤20 mg | 1 month |